(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of 10.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Xencor's revenue in 2026 is $125,576,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $9,147,528,817, with the lowest XNCR revenue forecast at $3,539,689,556, and the highest XNCR revenue forecast at $21,506,556,767. On average, 15 Wall Street analysts forecast XNCR's revenue for 2027 to be $10,234,407,491, with the lowest XNCR revenue forecast at $4,049,246,441, and the highest XNCR revenue forecast at $22,146,803,111.
In 2028, XNCR is forecast to generate $12,665,583,473 in revenue, with the lowest revenue forecast at $3,853,065,573 and the highest revenue forecast at $30,355,597,310.